Respuesta a la quimioterapia de Cancer Stem Cells (CSC) de cáncer de vejiga

EDUARDO IMANOL AGÜERO; DENISE BELGOROSKY; YANINA LANGLE; MACARENA ZAMBRANO; MARIANELA SCIACCA; CATALINA LODILLINSKY; EDUARDO SANDES; BETIANA LERNER; MAXIMILIANO PÉREZ; ANA MARIA EIJÁN

Simposio; saic 2018; 2018

Introduction: Bladder Cancer (BCa) is in one of the most common tumors of the urogenital male tract and an important worldwide cause of death, being the muscle Invasive, is one of the worst prognosis. The standard treatment is the radical cystectomy, although, alternative treatments are being tried in order to provide better standard of living to the patients, such as tumor transurethral resection followed by radiotherapy and chemotherapy. Cancer Stem Cells (CSC) are a minority tumor cell population, associated to the lack of treatment response. The development of an in vitro assay that can predict treatment response, would be useful for patients with this pathology. Objective: Evaluate CSC modulation under treatment with chemotherapy drugs like Doxorubicin (Doxo) and Cisplatin (CisPt) using a murine BCa cell line (MB49-I). Results: Through a cell viability assay in monolayer, measured by MTS, half minimal inhibitory concentrations (IC50) were obtained, being 0,1µM for doxorubicin and 9 µM for cisplatin. Cancer sphere forming assay in low adherence conditions, an accepted method for CSC quantification, was carried out and treating or not the cells seeded with IC50 of Doxo or CisPt. Sphere formation efficiency of control MB49-I was 13%. Both treatments reduced this efficiency by 95% (p